 VANCOUVER and HOUSTON , April 30, 2020 CNW - ESSA Pharma Inc. ESSA, or the Company Nasdaq: EPIX, TSX-V: EPI, a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the U.S. Food and Drug Administration FDA has notified the Company that it may proceed with its proposed clinical investigation of EPI-7386 for the treatment of metastatic castration-resistant prostate cancer mCRPC. ESSA previously announced on March 30 th, 2020 that it had filed an Investigational New Drug IND application for EPI-7386 with the FDA. 